Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Research

The small-molecule protein ligand interface stabiliser E7820 induces differential cell line specific responses of integrin α2 expression

Authors: Michael David Hülskamp, Daniel Kronenberg, Richard Stange

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

The mechanism of small-molecule stabilised protein-protein interactions is of growing interest in the pharmacological discovery process. A plethora of different substances including the aromatic sulphonamide E7820 have been identified to act by such a mechanism. The process of E7820 induced CAPERα degradation and the resultant transcriptional down regulation of integrin α2 expression has previously been described for a variety of different cell lines and been made responsible for E7820’s antiangiogenic activity. Currently the application of E7820 in the treatment of various malignancies including pancreas carcinoma and breast cancer is being investigated in pre-clinical and clinical trials. It has been shown, that integrin α2 deficiency has beneficial effects on bone homeostasis in mice. To transfer E7820 treatment to bone-related pathologies, as non-healing fractures, osteoporosis and bone cancer might therefore be beneficial. However, at present no data is available on the effect of E7820 on osseous cells or skeletal malignancies.

Methods

Pre-osteoblastic (MC3T3 and Saos-2) cells and endothelial (eEnd2 cells and HUVECs) cells, each of human and murine origin respectively, were investigated. Vitality assay with different concentrations of E7820 were performed. All consecutive experiments were done at a final concentration of 50 ng/ml E7820. The expression and production of integrin α2 and CAPERα were investigated by quantitative real-time PCR and western blotting. Expression of CAPERα splice forms was differentiated by semi-quantitiative reverse transcriptase PCR.

Results

Here we present the first data showing that E7820 can increase integrin α2 expression in the pre-osteoblast MC3T3 cell line whilst also reproducing canonical E7820 activity in HUVECs. We show that the aberrant activity of E7820 in MC3T3 cells is likely due to differential activity of CAPERα at the integrin α2 promoter, rather than due to differential CAPERα degradation or differential expression of CAPERα spliceforms.

Conclusion

The results presented here indicate that E7820 may not be suitable to treat certain malignancies of musculoskeletal origin, due to the increase in integrin α2 expression it may induce. Further investigation of the differential functioning of CAPERα and the integrin α2 promoter in cells of various origin would however be necessary to more clearly differentiate between cell lines that will positively respond to E7820 from those that will not.

Available only for authorised users

Fink EC, Ebert BL. The novel mechanism of lenalidomide activity. Blood. 2015;126(21):2366–9. https://doi.org/10.1182/blood-2015-07-567958 .CrossRefPubMedPubMedCentral

Valeur E, Narjes F, Ottmann C, Plowright AT. Emerging modes-of-action in drug discovery. Med Chem Comm. 2019;10:1550–68.CrossRef

Fischer ES, Park E, Eck MJ, Thomä NH. SPLINTS: small-molecule protein ligand interface stabilizers. Curr Opin Struct Biol. 2016;37:115–22. https://doi.org/10.1016/j.sbi.2016.01.004 .CrossRefPubMedPubMedCentral

Funahashi Y, Sugi NH, Semba T, Yamamoto Y, Hamaoka S, Tsukahara-Tamai N, et al. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Res. 2002;62(21):6116–23.PubMed

Semba T, Funahashi Y, Ono N, Yamamoto Y, Sugi NH, Asada M, et al. An angiogenesis inhibitor E7820 shows broad-Spectrum tumor growth inhibition in a xenograft model: possible value of integrin α2 on platelets as a biological marker. Clin Cancer Res. 2004;10(4):1430–8. https://doi.org/10.1158/1078-0432.CCR-0109-03 .CrossRefPubMed

Sawyer MB, Iqbal S, Lenz H, Lima CSR, Rossignol DP, Krivelevich I, et al. Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC). J Clin Oncol. 2010;28(15_suppl):3537. https://doi.org/10.1200/jco.2010.28.15_suppl.3537 .CrossRef

Mita M, Kelly KR, Mita A, Ricart AD, Romero O, Tolcher A, et al. Phase I study of E7820, an Oral inhibitor of integrin α-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin Cancer Res. 2011;17(1):193–200. https://doi.org/10.1158/1078-0432.CCR-10-0010 .CrossRefPubMed

Kerklaan BM, Slater S, Flynn M, Greystoke A, Witteveen PO, Megui-Roelvink M, et al. A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors. Investig New Drugs. 2016;34(3):329–37. https://doi.org/10.1007/s10637-016-0344-9 .CrossRef

Chilewski SD, Bhosale D, Dees S, Hutchinson I, Trimble R, Pontiggia L, et al. Development of CAPER peptides for the treatment of triple negative breast cancer. Cell Cycle Taylor & Francis. 2020;19(4):432–47. https://doi.org/10.1080/15384101.2020.1711579 .CrossRef

10.

Faust TB, Yoon H, Nowak RP, Donovan KA, Li Z, Cai Q, et al. Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15. Nat Chem Biol. 2019;355:1–13.

11.

Bier D, Thiel P, Briels J, Ottmann C. Stabilization of protein–protein interactions in chemical biology and drug discovery. Prog Biophys Mol Biol Elsevier Ltd. 2015;119(1):10–9. https://doi.org/10.1016/j.pbiomolbio.2015.05.002 .CrossRef

12.

Uehara T, Minoshima Y, Sagane K, Sugi NH, Mitsuhashi KO, Yamamoto N, et al. Selective degradation of splicing factor CAPERα by anticancer sulfonamides. Nat Chem Biol. 2017;13(6):675–80. https://doi.org/10.1038/nchembio.2363 .CrossRefPubMed

13.

Petroski MD, Deshaies RJ. Function and regulation of cullin–RING ubiquitin ligases. Nat Rev Mol Cell Biol. 2005;6(1):9–20. https://doi.org/10.1038/nrm1547 .CrossRefPubMed

14.

Jung D-J, Na S-Y, Na DS, Lee JW. Molecular cloning and characterization of CAPER, a novel coactivator of activating Protein-1 and estrogen receptors. J Biol Chem. 2002;277(2):1229–34. https://doi.org/10.1074/jbc.M110417200 .CrossRefPubMed

15.

Zutter MM, Santoro SA, Painter AS, Tsung YL, Gafford A. The human alpha 2 integrin gene promoter. Identification of positive and negative regulatory elements important for cell-type and developmentally restricted gene expression. J Biol Chem. 1994;269(1):463–9. https://doi.org/10.1016/S0021-9258(17)42373-8 .CrossRefPubMed

16.

Zutter MM, Painter AA, Staatz WD, Tsung YL. Regulation of alpha 2 integrin gene expression in cells with megakaryocytic features: a common theme of three necessary elements. Blood. 1995;86(8):3006–14. https://doi.org/10.1182/blood.V86.8.3006.3006 .CrossRefPubMed

17.

Han T, Goralski M, Gaskill N, Capota E, Kim J, Ting TC, et al. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science (80- ). 2017;356:eaal3755.CrossRef

18.

Sang Y, Yan F, Ren X. The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications. Oncotarget. 2015;6(40):42590–602. https://doi.org/10.18632/oncotarget.6052 .CrossRefPubMedPubMedCentral

19.

O’Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. Nucleic Acids Res. 2016;44(D1):D733–45. https://doi.org/10.1093/nar/gkv1189 .CrossRefPubMed

20.

Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. BBA - Rev Cancer. 1991;1072:129–57.

21.

Cheli Y, Kanaji S, Jacquelin B, Chang M, Nugent DJ, Kunicki TJ. Transcriptional and epigenetic regulation of the integrin collagen receptor locus ITGA1-PELO-ITGA2. Biochim Biophys Acta - Gene Struct Expr. 2007;1769:546–58.CrossRef

22.

Wu X, Cai J, Zuo Z, Li J. Collagen facilitates the colorectal cancer stemness and metastasis through an integrin/PI3K/AKT/snail signaling pathway. Biomed Pharmacother. 2019;114:108708. https://doi.org/10.1016/j.biopha.2019.108708 .CrossRefPubMed

23.

Ito K, Semba T, Uenaka T, Wakabayashi T, Asada M, Funahashi Y. Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models. Cancer Sci. 2014;105(8):1023–31. https://doi.org/10.1111/cas.12450 .CrossRefPubMedPubMedCentral

24.

Chung CH, Chang CH, Hsu CC, Lin KT, Peng HC, Huang TF. Aggretin Venom Polypeptide as a Novel Anti-angiogenesis Agent by Targeting Integrin alpha2beta1. Sci Rep. 2017;7:43612 Nature Publishing Group.CrossRefPubMedPubMedCentral

25.

Stange R, Kronenberg D, Timmen M, Everding J, Hidding H, Eckes B, et al. Age-related bone deterioration is diminished by disrupted collagen sensing in integrin α2β1 deficient mice. Bone. 2013;56(1):48–54. https://doi.org/10.1016/j.bone.2013.05.003 .CrossRefPubMed

26.

Wang D, Christensen K, Chawla K, Xiao G, Krebsbach PH, Franceschi RT. Isolation and characterization of MC3T3-E1 Preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J Bone Miner Res. 1999;14(6):893–903. https://doi.org/10.1359/jbmr.1999.14.6.893 .CrossRefPubMed

27.

Rodan SB, Imai Y, Thiede MA, Wesolowski G, Thompson D, Bar-Shavit Z, et al. Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. Cancer Res. 1987;47(18):4961–6.PubMed

28.

Williams RL, Risau W, Zerwes H-G, Drexler H, Aguzzi A, Wagner EF. Endothelioma cells expressing the polyoma middle T oncogene induce hemangiomas by host cell recruitment. Cell. 1989;57(6):1053–63. https://doi.org/10.1016/0092-8674(89)90343-7 .CrossRefPubMed

29.

Filipovic N, Ghimire K, Saveljic I, Milosevic Z, Ruegg C. Computational modeling of shear forces and experimental validation of endothelial cell responses in an orbital well shaker system. Comput methods Biomech biomed Engin. Taylor Francis. 2016;19:581–90.

30.

Goel G, Makkar HPS, Francis G, Becker K. Phorbol esters: structure, biological activity, and toxicity in animals. Int J Toxicol. 2007;26(4):279–88. https://doi.org/10.1080/10915810701464641 .CrossRefPubMed

31.

Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1-2):55–63. https://doi.org/10.1016/0022-1759(83)90303-4 .CrossRefPubMed

32.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 2001;25(4):402–8. https://doi.org/10.1006/meth.2001.1262 .CrossRefPubMed

33.

Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells. Science (80- ). 2014;343:301–5.CrossRef

34.

Gullberg DE, Lundgren-Åkerlund E. Collagen-binding I domain integrins — what do they do? Prog Histochem Cytochem. 2002;37(1):3–54. https://doi.org/10.1016/S0079-6336(02)80008-0 .CrossRefPubMed

35.

Kronenberg D, Michel PA, Hochstrat E, Wei M, Brinckmann J, Müller M, et al. Increased collagen turnover impairs tendon microstructure and stability in integrin α2β1-deficient mice. Int J Mol Sci. 2020;21:4–6.CrossRef

36.

Obata H, Hayashi K, Nishida W, Momiyama T, Uchida A, Ochi T, et al. Smooth muscle cell phenotype-dependent transcriptional regulation of the alpha1 integrin gene. J Biol Chem. 1997;272(42):26643–51. https://doi.org/10.1074/jbc.272.42.26643 .CrossRefPubMed

37.

Vigneault F, Zaniolo K, Gaudreault M, Gingras M-E, Guérin SL. Control of integrin genes expression in the eye. Prog Retin Eye Res. 2007;26(2):99–161. https://doi.org/10.1016/j.preteyeres.2006.10.004 .CrossRefPubMed

38.

Lu N, Heuchel R, Barczyk M, Zhang W-M, Gullberg D. Tandem Sp1/Sp3 sites together with an Ets-1 site cooperate to mediate alpha11 integrin chain expression in mesenchymal cells. Matrix Biol. 2006;25(2):118–29. https://doi.org/10.1016/j.matbio.2005.10.002 .CrossRefPubMed

39.

Lu N, Carracedo S, Ranta J, Heuchel R, Soininen R, Gullberg D. The human alpha11 integrin promoter drives fibroblast-restricted expression in vivo and is regulated by TGF-beta1 in a Smad- and Sp1-dependent manner. Matrix Biol. 2010;29(3):166–76. https://doi.org/10.1016/j.matbio.2009.11.003 International Society of Matrix Biology.CrossRefPubMed

40.

Xu J, Zutter MM, Santoro SA, Clark RA. A three-dimensional collagen lattice activates NF-kappaB in human fibroblasts: role in integrin alpha2 gene expression and tissue remodeling. J Cell Biol. 1998;140(3):709–19. https://doi.org/10.1083/jcb.140.3.709 .CrossRefPubMedPubMedCentral

41.

Engel BE, Welsh E, Emmons MF, Santiago-Cardona PG, Cress WD. Expression of integrin alpha 10 is transcriptionally activated by pRb in mouse osteoblasts and is downregulated in multiple solid tumors. Cell Death Dis. 2013;4:e938 Nature Publishing Group.CrossRefPubMedPubMedCentral

42.

Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer. 2008;8(11):880–7. https://doi.org/10.1038/nrc2505 .CrossRefPubMedPubMedCentral

43.

Läubli H, Borsig L. Altered cell adhesion and glycosylation promote Cancer immune suppression and metastasis. Front Immunol. 2019;10:2120. https://doi.org/10.3389/fimmu.2019.02120 .CrossRefPubMedPubMedCentral

44.

Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9–22. https://doi.org/10.1038/nrc2748 .CrossRefPubMedPubMedCentral

45.

Yang C, Zeisberg M, Lively JC, Nyberg P, Afdhal N, Kalluri R. Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res. 2003;63(23):8312–7.PubMed

46.

Ren D, Zhao J, Sun Y, Li D, Meng Z, Wang B, et al. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway. J Exp Clin Cancer Res. 2019;38:1–18.CrossRef

47.

Yang Q, Bavi P, Wang JY, Roehrl MH. Immuno-proteomic discovery of tumor tissue autoantigens identifies olfactomedin 4, CD11b, and integrin alpha-2 as markers of colorectal cancer with liver metastases. J Proteomics. 2017;168:53–65 Elsevier B.V.CrossRefPubMed

48.

Huang G, Zhou Z, Wang H, Kleinerman ES. CAPER-α alternative splicing regulates the expression of vascular endothelial growth factor165 in Ewing sarcoma cells. Cancer. 2012;118(8):2106–16. https://doi.org/10.1002/cncr.26488 .CrossRefPubMed

Title: The small-molecule protein ligand interface stabiliser E7820 induces differential cell line specific responses of integrin α2 expression
Authors: Michael David Hülskamp
Daniel Kronenberg
Richard Stange
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08301-w

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

The combined effect of dichloroacetate and 3-bromopyruvate on glucose metabolism in colorectal cancer cell line, HT-29; the mitochondrial pathway apoptosis

Construction of a nine DNA repair-related gene prognostic classifier to predict prognosis in patients with endometrial carcinoma

Correction to: Mitochondrial DNA abnormalities provide mechanistic insight and predict reactive oxygen species-stimulating drug efficacy

The expression and prognostic value of the epidermal growth factor receptor family in glioma

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations